Press release
112KB
maggio 04, 2021 - Bosch
World Asthma Day 2021: Asthma sufferers would welcome more digital solutions, Bosch survey suggests
Comunicato Stampa disponibile solo in lingua originale.
Bosch home measuring device Vivatmo me uses digital treatment approach to help asthmatics
1. Asthma – a common disease
The Global Asthma Network estimates that there are some 339 million asthma sufferers worldwide, which makes this respiratory disease one of the most frequent chronic health conditions. Moreover, a further 100 million people are expected to contract this condition by 2025. In Germany alone, 3.5 million people are receiving medical treatment for asthma – 4.2 percent of the population. Asthma does not just mean restrictions in sufferers’ private lives. Hospitalization, visits to physicians, and drugs, not to mention the loss of labor productivity, mean that the economic burden of such a chronic disease is considerable. Between 1999 and 2002, the total cost incurred by 15- to 69-year-old Europeans came to some 19.3 billion euros. According to the Global Asthma Network, treatment of this condition focuses on monitoring asthma symptoms and avoiding asthmatic attacks. The Bosch subsidiary Bosch Healthcare Solutions offers asthmatics support in the shape of its Vivatmo me breath-gas analyzer. This device allows them to monitor themselves at home and to detect a worsening of their condition at an early stage. By using what is known as FeNO or NO testing, the analyzer relies on a new examination method that allows patients to accurately determine the level of inflammation themselves. The findings can be documented in an app and shared with a doctor.
2. Asthmatics would welcome digital solutions for self-testing
More and more patients are demanding that digital solutions be used in medical treatment. The opinion research company Civey recently carried out a representative online survey of 1,000 respondents for Bosch Healthcare Solutions. More than half the respondents (52 percent) said that, in the case of asthma, they would welcome modern digital aids such as apps to help them keep track of the course of their condition. At 62 percent, the willingness to self-monitor is particularly high among 40- to 49-year-olds. On average, the desire for more medical test devices for the home is also higher in this demographic.
3. FeNO or NO tests as a new monitoring method
What are known as FeNO or NO tests are a new method for monitoring the treatment of asthma. They allow patients to test the level of an inflammation marker in their lungs. The inflammation associated with asthma causes the production of nitric oxide (NO) in the mucus membranes of the respiratory tract. The amount of this gas can be measured as fractional exhaled nitric oxide (FeNO). The higher the NO level, the more severe the inflammation. In healthy adults, the FeNO level is generally less than 25 ppb (parts per billion). FeNO levels of more than 50 ppb are a symptom of an acute allergic airway inflammation: “We have been measuring FeNO levels in daily practice since the first measurement devices came onto the market. Our experience with allergic asthma patients has been very positive. In this context, self-testing improves compliance, and helps patients and physicians to understand each other better,” says the lung specialist Dr. Michael Barczok, who also co-founded the lung center in Ulm, Germany. Bosch Healthcare Solutions’ measuring device Vivatmo me allows asthmatics to measure their NO levels at any time and in any place. It is the world's first FeNO meter for home use.
4. FeNO and NO tests still relatively unknown in asthma treatment
For patients, NO tests are both stress-free and simple to perform. Although they are available to patients in Germany, they are not covered by statutory health insurance programs. The latest German national treatment guidelines also list the determination of fractional exhaled nitric oxide as part of the initial diagnostic procedure for asthma, and recommend repeated testing.
Nonetheless, many patients have never heard of this method for monitoring asthma. To their knowledge, only 20 percent of those who keep themselves regularly informed about asthma have had a FeNO test, the Bosch survey found. Half (49 percent) of the respondents have never been given a FeNO or NO test by their doctor. And when asked about this test, a further 31 percent gave no reply or had never heard of it.
5. Closely meshed treatment can positively influence course of disease
The Bosch survey suggests that half the respondents are satisfied with their medical care and value personal contact with their physician. Vivatmo me helps patient-physician communication by digitally managing test results in an asthma diary app and sharing them with the physician as required. The app has already won an award, the PneumoDigital quality seal, for its user-friendliness. “By using Vivatmo me to monitor their results themselves, asthmatics can regain control over their condition and get a better idea of what their ‘invisible enemy’ – airway inflammation – is up to. For many asthma sufferers, this is a crucial step toward dealing better with their disease and getting a grip on it,” says Dr. Michael Barczok, when asked about his experience with Vivatmo me and its digital treatment approach.
Close monitoring of inflammation levels via FeNO measurement has a positive impact on potential asthma in pregnant women's children as well. According to an Australian study, a medical diagnosis of asthma in these children was reduced by almost 50 percent by preschool age.
6. Nearly 40 percent of respondents have reservations about corticosteroids
The German national guidelines for asthma treatment set out a phased plan for the treatment of adult asthma. The use of inhaled corticosteroids (ICS) is common to each phase. Nearly 40 percent of those polled on behalf of Bosch expressed their reservations about the use of corticosteroids in asthma treatment. These reservations become stronger with increasing age. Vivatmo me gives patients a clear idea of the course of their illness. Deterioration can be detected early on and treated in time with their physician. “The fight against asthma will not be won with beta agonists and corticosteroids. I believe it makes more sense to intervene earlier and, through continuous treatment in close consultation with the patient, to prevent acute symptoms from appearing in the first place,” says Barczok, summing up the benefits of close monitoring.
7. Vivatmo me available in Germany and Austria
Vivatmo me has been available in Germany and Austria since March 2020. In a next step, it is planned to obtain approval in other markets, such as the United States. The development of the Vivatmo system was able to draw on the Bosch Group’s experience and core competencies in sensor and microsystems technology, miniaturization, algorithm development, smart connectivity, and the manufacture of highly precise, complex products that meet the company’s exacting quality standards.
bhcs vivatmo me-arzt sportler remote-2226-edited
6000x4000, 7MB
bhcs vivatmo me-selbstbestoffene arzt vivatmo me-0724-edited
6000x4000, 5MB
bhcs vivatmo me-stills vivatmo-2251-edited
6000x4000, 7MB
vivatmo me feno-messgeraet bosch
7689x5128, 9MB
yvonne sofa vivatmo pusten
6000x3376, 4MB
bhcs factsheet-asthma-de-210428-3-web
3508x4664, 3MB
bhcs factsheet-asthma-en-210428-3-web
3508x4664, 3MB
News correlate |
||
|
|
|
aprile 19, 2024
|
aprile 18, 2024
|
aprile 17, 2024
|
|
Bosch e R-Biopharm investono insieme 150 milioni di euro nello sviluppo di nuovi test PCR e in attività di marketingIl test PCR pe... |
Esercizio 2023: fatturato salito a 91,6 miliardi di euro / EBIT aumentato al 5,3% su base annuaProspettive contenute per il 2024: ... |
Il continuo impegno di Bosch nella ricerca di soluzioni volte a creare un mondo più sano e sostenibile è più di una missione, rapp... |
Scarica tutto 
Ti potrebbe interessare anche |
||
|
|
|
aprile 17, 2024
|
aprile 17, 2024
|
aprile 17, 2024
|
|
Bosch presenta a EuroCucina 2024 le ultime novità della gamma frigoriferi XXL: i nuovi frigoriferi combinati da incasso da 70 cm e... |
[ 16-21 Aprile 2024, Rho Fiera Milano, Pad. 4, Stand C05 ]“Live Responsibly #LikeABosch” è il messaggio che Bosch rilancia in occa... |
Nelle case moderne la cucina è sempre più spesso integrata alla zona living e questo porta a considerare attentamente la configura... |
Inglese 
Scarica tutto 
Condividi
Condividi via mail 
Automotive
Sport
Events
Art&Culture
Design
Fashion&Beauty
Food&Hospitality
Tecnologia
Nautica
Racing
Excellence
Corporate
OffBeat
Green
Gift
Pop
Heritage
Entertainment
Health & Wellness